Ethacrynic acid (ECA) is a new promising drug for glaucoma. This sulfhydryl compound exerts its hypotensive effect by directly affecting the cytoskeletal properties of both trabecular meshwork cells and the inner wall of Schlemm's canal. In fact, its action resembles a 'pharmacologic trabeculocanalotomy' with subsequent increase in outflow facility. This unique mode of action may put ECA at the front of glaucoma therapy in the future.
|Ophthalmology Clinics of North America
|Published - 1995